TSPAN2

Across TCGA pan-cancer cohorts, TSPAN2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TSPAN2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TSPAN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TSPAN2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, GBM, and PDAC are the cancer types where TSPAN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.866	1.000	.005	24	view →
GBM	OS	Median	All	0.977	0.649	.004	8	view →
PDAC	DFS	Median	All	0.122	0.789	.038	6	view →
LSCC	OS	Median	III,IV	0.446	0.891	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TSPAN2–LUAD (DFS)

Open the LUAD breakdown →